OptimizeRx Sets Fourth Quarter and Full Year 2020 Conference Call for Wednesday, February 24, 2021 at 4:30 p.m. ET
February 18 2021 - 7:31AM
OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of
digital health solutions for life science companies, physicians and
patients, will hold a conference call on Wednesday, February 24,
2021 at 4:30 p.m. Eastern time to discuss its results for the
fourth quarter and full year ended December 31, 2020. OptimizeRx
management will host the call, followed by a question and answer
period.
As earlier reported, the company expects to report record
revenue for the quarter of more than $16 million, up 117% from the
same year-ago quarter, along with positive GAAP net income.
On the call, management will review how this organic growth has
been driven by the increasing use of the company’s digital health
network by life science companies, allowing them to engage
providers and patients at key touchpoints along the care
journey.
The full financial results for the quarter and full year 2020
will be issued in a press release prior to the call.
Conference Call InformationDate: Wednesday,
February 24, 2021Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific
time)Toll-free dial-in number: 1-800-437-2398International dial-in
number: 1-323-289-6576Conference ID: 9166514
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization. If you have any difficulty connecting with the
conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after 7:30 p.m. Eastern
time on the same day through March 17, 2021, as well as available
for replay via the Investors section of the OptimizeRx website at
www.optimizerx.com/investors.
Toll-free replay number: 1-844-512-2921International replay
number: 1-412-317-6671Replay ID: 9166514
About OptimizeRxOptimizeRx is a digital
health company that provides communications solutions for life
science companies, physicians and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients
through a proprietary network, the OptimizeRx digital
health platform helps patients afford and stay on medications. The
platform unlocks new patient and physician touchpoints for life
science companies along the patient journey, from point-of-care, to
retail pharmacy, through mobile patient engagement.
Important Cautions Regarding Forward-Looking
Statements Certain information contained in this press
release includes “forward-looking statements” within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to the gross proceeds we expect to receive from
the offering, the expected use of the net proceeds from the
offering and the expected date of the closing of the offering. We
may, in some cases use terms such as “expects,” “plans,” “will” or
other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current expectations that
involve risks, potential changes in circumstances, assumptions and
uncertainties. Any or all of the forward-looking statements may
turn out to be wrong, or be affected by inaccurate assumptions we
might make or by known or unknown risks and uncertainties as a
result of various important factors, including the uncertainties
related to market conditions and the completion of the public
offering on the anticipated terms, or at all. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to our business in general,
please refer to our preliminary prospectus supplement filed with
the Securities and Exchange Commission (SEC) on February 8, 2021
under the heading “Risk Factors” and those documents incorporated
by reference therein, which includes our Annual Report on Form 10-K
filed with the SEC on March 26, 2020. You are cautioned not to
place undue reliance on these forward-looking statements, which are
made only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568
x807dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557Email Contact
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2024 to May 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From May 2023 to May 2024